Incannex Announces Initiation of Research Coverage by Alliance Global Partners

About this update from Incannex Healthcare Inc.

MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company. The research report, authored by AGP Managing Director and Senior Biotechnology Analyst James Molloy, provides an independent assessment of Incannex’s clinical pipeline, development strategy, market opportunities and future growth prospects. Research Coverage Highlights Rating: BUYPrice Target: US$18.00 per shareAnalyst: James Molloy, Alliance Global PartnersReport Date: June 8, 2026 Incannex believes the initiation of coverage by AGP represents an important milestone in expanding awareness of the Company’s clinical programs and investment proposition among institutional and retail investors. The report includes discussion of the Company’s lead obstructive sleep apnoea program, IHL-42X, currently being advanced through the DReAMzz dose optimisation study, as well as PSX-001, the Company’s synthetic psilocybin program for generalized anxiety disorder. Joel Latham, President and Chief Executive Officer of Incannex, commented: “We are pleased AGP has elected to initiate research coverage and appreciate the time and diligence their team has dedicated to understanding our business, clinical programs and long-term strategy.” “As we continue advancing IHL-42X and PSX-001 through development, we believe increased research coverage can help broaden investor awareness of the significant unmet needs we are seeking to address and the substantial commercial opportunities represented by our pipeline.” Investors may contact Alliance Global Partners (www.allianceg.com) directly to obtain a copy of the report. Analyst Disclaimer The information above regarding analyst coverage is solely for informational purposes and is not intended as a solicitation to make investments. Any opinions, estimates or forecasts regarding Incannex’s performance made by analysts are theirs alone and do not represent opinions, forecasts or predictions of Incannex or its management. Incannex does not by its reference above, or by distribution, imply its endorsement of or concurrence with such informatio...

View stock analysis, news, and events for Incannex Healthcare Inc.